<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180089</url>
  </required_header>
  <id_info>
    <org_study_id>PROGAST</org_study_id>
    <nct_id>NCT00180089</nct_id>
  </id_info>
  <brief_title>Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation</brief_title>
  <official_title>Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether orale budesonide is effective in the
      prevention of acute gastrointestinal graft-versus-host disease (GVHD) following allogenic
      stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether orale budesonide is effective in the
      prevention of acute gastrointestinal graft-versus-host disease (GVHD) following allogenic
      stem cell transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date>January 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of acute gastrointestinal (GI) GVHD in the active group versus placebo group</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>grade of acute GI GVHD</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of chronic GI GVHD</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of infectious complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall and disease-free survival 1 yr after transplant</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Leukemia</condition>
  <condition>Graft-Versus-Host Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  planned allogenic stem cell or bone marrow transplantation

          -  HLA identity (max. 1 mismatch)

          -  standard GVHD prophylaxis with cyclosporin A or tacrolimus combined with MTX, +/- ATG
             or Campath1H

          -  written informed consent

        Exclusion Criteria:

          -  history of allogenic transplantation

          -  in vitro T-cell depleted transplant

          -  pretreatment with budesonide within the previous 4 weeks

          -  known intolerance to budesonide

          -  gastrointestinal infections

          -  portal hypertension

          -  concomitant infectious diseases

          -  liver cirrhosis, impaired liver function

          -  severe mental disorder

          -  lack of compliance

          -  drug or alcohol abuse

          -  pregnancy, lactation

          -  childbearing potential without effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Miehlke, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Department I, Technical University Hospital, Dresden, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Department I, Technical University Hospital</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>March 29, 2010</last_update_submitted>
  <last_update_submitted_qc>March 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2010</last_update_posted>
  <keyword>graft-versus-host disease</keyword>
  <keyword>budesonide</keyword>
  <keyword>stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

